---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-275395"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:36:07.345989+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q3 net loss $21.7M, cash $165.5M; Phase 3 melanoma trial fully enrolled

## Summary
- Net loss $21.7M in Q3 2023 vs $15.7M Q3 2022; R&D expenses $17.7M (up from $10.0M) driven by Phase 3 trial.
- Cash and equivalents $165.5M at Sept 30, 2023, including $75M private placement; cash runway into Q4 2025.
- Completed enrollment of 380 patients in pivotal Phase 3 (IO102-IO103 + pembrolizumab) for advanced melanoma; interim ORR expected Q3 2024, PFS H2 2025.
- Appointed Helen Collins, MD to board; she serves as Chair of R&D Committee and brings extensive oncology drug development experience.
- Presented encouraging preliminary Phase 2 data at WCLC and ESMO; three non-clinical posters at SITC 2023.

## SEC filing metadata
- accession: 0001193125-23-275395
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/d893930d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-275395
- JSON: https://secwatch.observer/filing/0001193125-23-275395.json
- Plain text: https://secwatch.observer/filing/0001193125-23-275395.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported the quarter ended September 30, 2023 results: net income $21.7 million.
  - Period: the quarter ended September 30, 2023
  - Net income: $21.7 million
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2023, was $21.7 million, compared to $15.7 million for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm
- Executive change
  Helen Collins was appointed as Class II Director at IO Biotech, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On November 9, 2023, the Company increased the size of the Board from seven to eight directors, and appointed Helen Collins, M.D. as a Class II director of the Company to fill the vacancy, effective as of that same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523275395/0001193125-23-275395-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.